[ad_1]
hapabapa/iStock Editorial via Getty Images
The U.S. Food and Drug Administration (FDA) on Thursday approved Cobenfy (xanomeline and trospium chloride), developed by Bristol-Myers Squibb (NYSE:BMY), as a novel treatment for adults with the psychiatric disorder schizophrenia.
Bristol-Myers (BMY) traded ~5% higher in
[ad_2]